Periodontal Disease in a Patient Receiving Bevacizumab
Author Information
Author(s): Gujral Dorothy M, Bhattacharyya Sanjeev, Hargreaves Peter, Middleton Gary W
Primary Institution: St Lukes Cancer Centre, Royal Surrey County Hospital, Guildford, UK
Hypothesis
Is bevacizumab associated with the development of periodontal disease in patients?
Conclusion
The case suggests a potential link between bevacizumab treatment and periodontal disease, which remained stable after discontinuation of the drug.
Supporting Evidence
- The patient developed periodontitis while receiving bevacizumab for lung cancer.
- The periodontal disease remained stable after discontinuation of the drug.
- This is the first reported case of periodontal disease associated with bevacizumab.
Takeaway
A woman developed gum disease while taking a cancer drug called bevacizumab, but her condition didn't get worse after she stopped the drug.
Methodology
Case report of a patient receiving bevacizumab for lung cancer and developing periodontal disease.
Potential Biases
Potential confounding factors related to the patient's medical history and other risk factors for periodontal disease.
Limitations
The case is based on a single patient, making it difficult to generalize the findings.
Participant Demographics
One 43-year-old female patient.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website